Thursday, 24 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?

View original at finance.yahoo.com
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Positioned to launch around 20 drugs over the next few years, with many having blockbuster potential

    80% confidence

  • Targeting $2 billion in annualized cost savings by the end of 2027

    80% confidence

  • Operating expenses expected to decline in 2026, supporting margin expansion

    80% confidence

  • Zacks Consensus Estimate for BMY's 2026 EPS suggests increase of 0.33%

    80% confidence

  • Zacks Consensus Estimate for BMY's 2026 sales implies year-over-year decrease of 2.32%

    80% confidence

  • Keytruda targets peak sales of $35 billion by 2028

    80% confidence

  • Keytruda will lose patient exclusivity in 2028

    80% confidence

  • Annual revenue guidance of $46.0-$47.5 billion for 2026

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 EPS suggests decline of 38.75%

    80% confidence

  • Expects headwind of approximately $2.5 billion from generic competition in 2026

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 sales implies year-over-year increase of 2.59%

    80% confidence

  • Phase III pipeline has almost tripled since 2021

    80% confidence

  • Achieved approximately $1 billion in savings in 2025

    80% confidence

  • BMY's relatively attractive valuation and more favorable 2026 outlook position it as the more compelling investment choice versus MRK at present

    80% confidence

  • Legacy Portfolio sales expected to decline 12-16% in 2026

    80% confidence

  • Expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? — Source | Via News | ViaNews EU